Wockhardt Latest Indian Drug Maker To Split Off R&D
This article was originally published in PharmAsia News
Executive Summary
India's Wockhardt plans to form its research and development business into a new company to be listed on the stock exchange in 2009. Wockhardt would become the latest of several major drug makers in India to split their R&D work from their other drug-development activities. The separation is seen by companies as a way to raise more funds to support research while reducing the risks to core business. But one analyst said Wockhardt is not likely to see the benefits of delisting as much as its rivals because its drug pipeline is small. (Click here for more
You may also be interested in...
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.
GLP-1 Coverage Restrictions In Medicare Part D Surge As Demand For Obesity Drugs Grows
A major shift from unfettered coverage to prior authorizations was recorded by MMIT over the past year for the leading GLP-1/GIP agonist diabetes drugs. Public interest in using the drugs off label for weight loss drove the change.